Please enter your details to request more information

PRIVATE INVESTOR ENQUIRY

Request BioLabs investment information

  1. Tell us how you would like to be contacted.
  2. Receive a response from the BioLabs investor-enquiries team.
  3. Where applicable, complete the required investor eligibility and risk processes before access to offer documents.

7.50p

Share Price

£18.65m

Equidam Valuation*

£980,000

Raised to Date*

130

Investors*

AI-Led Plant Molecular Farming

BIOLABS CORP LTD · INVESTMENT OPPORTUNITY

BioLabs is advancing an AI-enabled platform that combines computational biology, precision cultivation and autonomous process development to investigate the production of high-value therapeutic proteins, peptides and biomedical molecules.

Engineering the next generation of intelligent bioproduction.

Plant-based production

AI-enabled research

High-value molecules

Earth & space applications

Why BioLabs?

Our Plant Molecular Farming research brings AI-assisted biological design together with controlled cultivation, BioCube technology and laboratory analysis, targeting new approaches to high-value biological production.

  • Precision cultivation
  • AI-led research
  • High-value molecules
  • Space R&D

What are you investing in?

BioLabs Corp Ltd is the proposed share issuer. The investment is in shares in the company itself — not a subscription to a scientific product, and not direct ownership of patents or equipment held by other parties.

THE INVESTMENT EXPLAINED

01

Equity ownership

A subscription for shares in BioLabs Corp Ltd, subject to the current offer's verified terms and supporting documents.

Research and development of Plant Molecular Farming, with BioCube, computational biology, BPS and analytical science as enabling capabilities.

AI-enabled PMF

02

Qualifying share issues can offer UK tax relief to eligible investors. Existing advance assurance does not guarantee eligibility for this issue.

Potential EIS relief

03

Adjust the example investment and tax-rate assumptions to understand the conditional reliefs that may apply to qualifying Enterprise Investment Scheme (EIS) shares. This is not a quotation, a projection of returns or a confirmation of BioLabs' current-round eligibility.

Explore what potential EIS relief could mean

INVESTMENT & TAX-RELIEF EXPLORER

This is a calculation example only, not a subscription request. The share issue, investment minimum, investor eligibility and actual tax position all require separate confirmation.

Your full investment / original capital at risk£25,000You can lose the entire sum invested.
Potential EIS Income Tax relief, if eligible (30%)£7,500Not guaranteed; depends on sufficient liability and qualification.
Illustrative cost after assumed initial relief£17,500Not a guaranteed net cost or limit on losses.
Potential additional tax saving from qualifying loss relief£7,000Only if shares become worthless and loss relief is available at the selected rate.

Important assumptions and risks. The calculator uses the general 30% EIS initial relief rate and a simplified loss-relief illustration: (investment less initial relief) multiplied by your selected marginal Income Tax rate. Actual relief depends on HMRC qualification, the investor's personal tax liability and claims, shareholding conditions, restrictions and possible withdrawal. The full amount invested remains exposed to loss. Neither tax relief nor a tax-free gain is guaranteed. Qualifying EIS share gains can potentially be exempt from Capital Gains Tax after the relevant holding period and other conditions, but this calculator does not assume that outcome. No commercial returns or exit value are projected. Seek independent tax and financial advice before investing.

The Plant Molecular Farming (PMF) Process

Our Technology Platform

Space Biomanufacturing R&D

NASA Next STEP-3 LEIA

BioLabs and CAVU Aerospace UK submitted a development-stage response to NASA NextSTEP-3 LEIA Topic 4 describing an AI-enabled autonomous biomanufacturing architecture: computational design, cultivation, biological processing, monitored incubation and automated harvest/QC.

UK Space Agency

UK Space Agency engagement remains at the exploratory outreach stage, seeking relevant research and technology-development opportunities; no formal project or funding is claimed.

Development-stage activity. No NASA or UKSA selection, contract, funding, endorsement or flight validation is claimed.

11 US PATENTS PENDING

Five US cultivation/equipment applications + six BPS applications. Dr Paul Hilton personally owns the eleven US provisional patent applications, spanning precision cultivation, closed-loop biological production and proposed automated monitoring/QC. They are pending, not granted; any rights available to BioLabs Corp Ltd require separate evidence of assignment or licence.

SCIENTIFIC LEADERSHIP

Dr Mark Haislund

Head of Dietetics*

Chief Scientist*

Dr Paul Hilton

The Investment Case

An opportunity to explore investment in BioLabs Corp Ltd, a UK biotechnology company developing AI-enabled Plant Molecular Farming research and production technologies.

*Equidam provides an estimate, not the valuation implied by this share issue. Share price, fundraising totals, investor count, EIS advance assurance scope and any MHRA-licensed distribution relationship require final source verification. FCA authorisation is not FCA endorsement of the shares.

Current stated share price*

7.50p

Equidam valuation estimate*

£18.65m

Capital reported raised*

£980,000

Investors reported*

130

Understanding potential EIS tax relief

The UK Enterprise Investment Scheme can provide 30% Income Tax relief on qualifying share subscriptions, where the company, share issue and investor meet the relevant conditions. BioLabs has received advance assurance for an earlier proposal; eligibility of the current share issue has not yet been confirmed. Tax relief is not a substitute for assessing investment risk. No tax outcome is guaranteed.

To be able to deal with your enquiry effectively we will need to contact you via telephone and/or email. By enquiring you consent to being contacted and you consent to your data being stored in accordance with European GDPR regulations. Privacy Policy

Disclaimer: Any person accessing the website and considering potential investment opportunities featured on the website should make their own commercial assessment and could benefit from the advice of an appropriately authorised or regulated financial advisor. This website should not be construed as advice or a personal recommendation to any prospective investor. Investments of this nature carry risks to your capital and can go up or down. Past performance is not indicative of future results.